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Novelty and Impact: We assessed the impact of HRs expression on tumour behavior and treatment outcomes in 738 
HER2+ metastatic breast cancer patients treated with new generation anti-HER2 agents in a real world setting. 
Distinct HR expression patterns significantly affected the natural history of disease and the amount of benefit in 
terms of progression free and overall survival from pertuzumab-based regimens and T-DM1 treatments, thus giving 
some hints on an unmet need for better optimizing their sequential use. 
Abbreviations: HER2 = human epidermal growth factor receptor 2; BC = breast cancer; IHC = immunohistochemistry; 
PFS = progression free survival; HR = hormone receptor; OS = overall survival; ER = estrogen receptor; PgR = 
progesterone receptor; TP = triple positive; FISH = fluorescence in situ hybridization; CISH = cromogenic in situ 
hybridization 
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ABSTRACT 
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based 
regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by 
immunohistochemistry (IHC). The median progression free survival at first-line (mPFS1) was 12 months. Pertuzumab 
as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs 9 months, p=0.0001), regardless 
of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was 
more favorable with T-DM1 compared to  other agents (7 vs 6 months, p=0.03). There was no PFS2 gain in patients 
with tumors expressing both hormonal receptors (HRs) (p=0.17), while a trend emerged for tumors with one HR 
(p=0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p=0.04). Median overall survival (mOS) was 
74 months, with no significant differences by IHC subtypes. Survival  rates at 2 and 3 years in patients treated with T-
DM1 in second-line following pertuzumab were significantly lower compared to pertuzumab-naïve patients(p=0.01). 
When analyzed  by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p=0.02 and 
p=0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-
related  outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate 
analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our 
This article is protected by copyright. All rights reserved.
findings and clarify the interplay between HER2 and estrogen receptor (ER) pathways in HER2-positive (mbc) 
patients. 
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INTRODUCTION 
Amplification or over-expression of the human epidermal growth factor receptor 2 (HER2) is observed in 
approximately 20% of breast cancers (BCs), and is often associated with an aggressive clinical behavior and poor 
outcomes [1]. When overexpressed, the HER2 oncogene is the dominant driver of BC biology, and treatment 
strategies targeting HER2 have  become the standard of care in all the disease settings since 2006 [2]. Currently, four 
anti-HER2 agents are licensed in Europe: trastuzumab, lapatinib, pertuzumab and T-DM1. The use of anti-HER2 
agents combined or not with chemotherapy has dramatically improved prognosis in all stages of HER2-positive BC [3-
7]. 
About half of HER2-positive BCs also express hormone receptors (HRs)[8]. The coexistence of both estrogen 
receptors (ER) and progesterone receptors (PgR) expression and overerexpression/amplification of HER2 is the 
hallmark of  the subgroup called "triple positive" (TP) breast cancer. Even though treatment with anti-HER2 agents 
has shown benefit independently on HR status, the cross-talk between the two downstream pathways has an impact 
on the natural history of the disease and magnitude of treatment-benefit. 
In the metastatic setting, recent reports of outcomes by tumor subtype demonstrated that HR-positive/HER2-
positive tumors usually exhibit different behaviors and response to trastuzumab-based therapy, as well as distinct 
timings and patterns of relapse compared to HR-negative/HER2-positive tumors [9,10]. In the CLEOPATRA trial, the 
addition of pertuzumab to a first-line regimen with trastuzumab and docetaxel did not show any advantage in terms 
of overall survival (OS) in the subgroup of patients with ER and/or PgR-positive tumors (HR 0.73; 95%CI, 0.50-1.06) 
[9]. Conversely, in the Emilia and in the TH3RESA trials, patients received a significant PFS and OS benefit from the 
administration of T-DM1 regardless of HRs expression [7;11]. Yet, no data on novel HER2–blocking agents’ outcomes 
have been specifically reported on tumors overexpressing HER2 and expressing both HRs, i.e., TP tumors. So, we 
conducted a retrospective analysis on HER2-positive metastatic patients treated with pertuzumab-based regimens 
and/or T-DM1 according to standard clinical practice, and we specifically focused on whether the expression of HRs 
defines distinct subtypes with different biological behaviors and patterns of response/resistance to novel HER2-
blocking agents in HER2-positive metastatic BCs. 
 
MATERIALS AND METHODS  
Our cohort included 738 HER2-positive metastatic BC patients consecutively recruited and treated with pertuzumab-
based regimens and/or T-DM1 in any treatment line according to routine practice at 45 Italian oncologic centers 
from December 2003 through November 2017. The observational study was carried out according to a retrospective 
approach. Written informed consents were obtained from all patients providing data to our analysis. Information on 
demographics, clinical, histopathological and immunohistochemical (IHC) features, anti-tumoral therapies and 
related outcomes were retrieved from the patients’ medical records by specifically trained research assistants. All 
included patients were treated for a metastatic disease (defined as a BC spread over the mammary gland and the 
pertinent locoregional lymph nodes, including the supraclavicolar ones). Each patient was evaluated during 
treatment according to the follow-up strategies of each center. In all cases clinical evaluation, bone scan, 
computerized tomography (CT) and/or positron emission tomography (PET) – CT were performed at least every 3- 
months. Clinical response was evaluated by RECIST criteria Anonymized data were entered into a dedicated database 
with a SPSS operating interface. Median follow up was calculated starting from diagnosis of metastatic disease to 
death or date at the last  follow up. Endpoints for efficacy outcome included progression free survival (PFS) and 
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overall survival (OS). Progression free survival for any specific line of treatment was calculated from the time of 
treatment start to the time of progression of disease, interruption of treatment for toxicity, death or lost to follow-
up. Overall survival was  calculated starting from diagnosis of metastatic disease to death or last follow-up. For both 
PFS and OS the median value, respectively median PFS (mPFS) and median OS (mOS), were calculated using the 
Kaplan-Meier limit product method. A further assessment of OS in different patient s’subsets was performed by 
calculating the OS rate at 2 years and 3 years. 
Pathology assessment was performed on surgical specimens of primary tumors by dedicated pathologists at the 
participating centers as per national standards. Estrogen receptor and PgR status were determined at each center by 
IHC according to local standards. Positivity was considered at a cutoff of ≥1 %. A positive HER2 status required an IHC 
score of 3+ or positive fluorescence in situ hybridization/cromogenic in situ hybridization (FISH/CISH). This study was 
approved by the institutional ethical committee of the coordinating center (IRCCS Regina Elena National Cancer 
Institute of Rome) and satellite centers, and was conducted in compliance with Helsinki Declaration. 
 
DATA AVAILABILITY 
Raw data were generated at Regina Elena National Cancer Institute - IFO and collected from other 44 italian cancer 
centers. Derived data supporting the findings of this study are available from the corresponding author E. K. on 
request. 
 
STATEMENT ON PREPRINT: 




Descriptive statistics were used to summarize patient- and disease relevant characteristics. The associations 
between variables were tested by Chi–square or Fisher’s exact test, according to the number and size of the groups 
compared. Survival estimates were computed by Kaplan–Meier product-limit and compared by log–rank test. 
Significance was set at p ≤ 0.05. The associations of interest were evaluated in light of the distinction of the overall 
study cohort into categories defined by molecular subgroups, with the inherent modalities being set based on the 
results of IHC analysis and according to the criteria fully reported in the prior paragraph (patients and methods). The 
impact of the most relevant variables on OS and PFS1 was tested in COX uni/multivariate models. Significance was 
set at p ≤ 0.05. The following variables were considered: ICH subgroup, age, PS, metastatic disease at diagnosis, 
number of metastatic sites, visceral metastasis, Ki-67, pertuzumab-based regimen as first-line of treatment, T-DM1 
as a second-line treatment (when testing for OS). The covariates with a significant effect on OS and PFS1 in 
univariate analysis were further tested  in multivariate analysis. The variable “ICH subgroup” was  included in the 
multivariate model independently on the results of univariate analysis. Our choice was  due to the relevance of this 
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From 2003 through 2017, 738 HER2-positive metastatic BC patients were retrospectively identified at 45 Italian 
cancer centers. Recruited patients had received at least one cycle of pertuzumab-based regimen and/or T-DM1. 
Main patient and tumor characteristics are listed in Table 1. The median age was 54 years, and 63.4% of these 
patients had an ECOG PS of 0. Three-hundred-nineteen (43.2%) patients had a TP breast cancer. One-hundred-sixty 
(21.7%) had a tumor expressing only one HR, and the remaining 259 patients (35.1%) had HRs negative tumours. The 
majority of the  patients had visceral metastases (68.7%), bone-exclusive disease was recorded in 51 patients (6.9%), 
and 239 patients (32.4%) had multiple metastatic sites. As shown in Table 2, after analyzing the distribution of 
metastatic sites as a function of the IHC characteristics, we observed a significantly higher rate of bone-only disease 
in TP and ER or PgR positive tumors compared to HRs negative tumors (8.8% and 9.2% versus 3.6%, respectively) 
(p=0.02). Brain metastases were more frequently observed in patients with ER or PgR-positive BCs and in HRs 
negative tumors than in patients with a TP subtype, even though this difference did not reach statistical significance 
(29.6% and 27.8%, respectively, versus 20.8%) (p=0.06). Conversely, no differences were highlighted in terms of 
visceral metastases distribution by HR status (p=0.94).  
Overall, our study cohort included 247 patients (34.3%) with de novo metastatic disease, 206 patients (28.6%) with 
metastasis occurrence within 3 years from diagnosis, and 268 patients (37.2%) with metastatic spread after at least 3 
years from initial BC diagnosis (supplementary Table 1). When analyzing our results by IHC subtype, we observed 
that in the TP subgroup almost half of the patients experienced metastasis after the first 3 years (47%), while only 
18.3% of patients experimented relapse within this same time-window, and in 34.1% of patients the disease was 
metastatic at the onset. Conversely, in patients with HRs negative tumors, we found a higher percentage of early 
relapses (40.8%) or de novo metastatic disease  (36.7%), compared to patients who developed metastases after the 
first 3 years (22.4%). Patients with ER or PgR positive tumors showed an intermediate behavior with respect to the 
previous two subsets. Their percentage of de novo metastatic disease was 28.7%, early relapses (within 3 years) 
were encountered for 27.3% of patients and the remaining 43.8% had a metastatic recurrence beyond the 3-year 
period. When we compared the clinical behavior between these three subsets, namely TP, only one HR positive and 
HRs negative patients, no differences were found regarding the percentage of patients with  metastatic disease at 
the diagnosis (p=0.27), while the tendency of TP and one HR positive BC patients to develop less frequently early 
relapses with respect to HRs negative patients was statistically significant (p=0.001), (supplementary Table 1). 
Among the 738 patients included in our cohort, 371 (50.3%)  received a pertuzumab-trastuzumab-taxane regimen, 
which was always administered in the first-line setting. Conversely, a total of 517 (70.1%) patients received T-DM1, 
delivered as any line of treatment. In more detail, the number of patients who received T-DM1 as a first-, second- 
and third-line was respectively 31 (4.2%), 371 (50.3%) and 96 (13.0%). The remaining 19 (2.6%) patients received T-
DM1 beyond the third-line of treatment. All the patients treated with T-DM1 in second-line or beyond had 
previously received a pertuzumab-trastuzumab-based or trastuzumab-based treatment as first-line. The small cohort 
of patients (31) who received T-DM1 as first-line regimen had experienced a recurrence while on or within 6 months 
from trastuzumab-based adjuvant treatment. Overall, a total of 531 (72.0%) patients received a second-line 
treatment, including or not T-DM1. Among the 371 patients who received T-DM1 as a second-line of treatment, 177 
had been previously treated with a pertuzumab-trastuzumab-based regimen as first-line, while 194 had been 
previously treated with a trastuzumab-based first-line regimen. Among the 531 patients having received second-line 
treatment, 160 received treatment different from T-DM1 (i.e, lapatinib/capecitabine, trastuzumab/chemotherapy). 
In these 160 patients first-line treatments were represented bya pertuzumab-based regimen in 109 of them, T-DM1 
in 25 , and other treatments in 26 patients (Figure 3). Patients with HRs-positive tumors received maintenance 
endocrine therapy concomitantly with maintenance pertuzumab/trastuzumab, or maintenance trastuzumab after 
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trastuzumab/chemotherapy regimen, whereas, patients treated with T-DM1, didn’t received maintenance endocrine 
therapy after T-DM1. Moreover, we must take into account that a portion of HRs positive patients after diagnosis of 
metastatic disease received endocrine therapy plus trastuzumab as first-line, delaying chemotherapy/Her2-block. 
Overall, median follow-up was 32.9 months (95%CI, 3-256).  
 
First-line treatment 
Among the 738 evaluable patients, mPFS at first-line treatment (mPFS1) was 12 months (95%CI, 11-13), with no 
significant differences among the IHC subtypes, being 12 months (95%CI, 11-13) in TP subtype, 12 months (95%CI, 
10-14) in ER or PgR positive, and 12 months (95%CI, 10-14) in HRs negative tumors (p=0.53). Among the 371 patients 
treated with a first-line pertuzumab-trastuzumab-based regimen, the overall mPFS was 16 months (95%CI, 13-19), 
with a significant improvement with respect to patients who didn’t receive pertuzumab-based but had received 
trastuzumab-based treatments, showing a mPFS of 9 months (95%CI, 8-10) (p=0.0001). The advantage in mPFS1 for 
patients that received pertuzumab is also shown by the PFS1 survival curve in Fig.1 A. The mPFS1 benefit related to 
pertuzumab  was observed in all the IHC subtypes at a statistically significant level, as it can be observed in Figures 
1B, 1C and 1 D, respectively for TP, ER or PgR positive, and HRs negative subgroups (see also Table 3). In the 
multivariate analysis (supplementary Table 2), the only two variables related to a worse PFS1 were: not having 
received a pertuzumab-based regimen as a first-line treatment (HR 1.7; 95% CI 1.4-2; p < 0.0001) and having de novo 
metastatic disease (HR 1.2; 95% CI 1.0 – 1.4; p = 0.042). The multivariate analysis showed no significant effect of the 
ICH subgroup categories on PFS1. 
 
Second-line treatment 
Among the 531 patients evaluable for second-line treatment outcome, the median PFS (mPFS2) was 7 months 
(95%CI, 6-8), with no differences by IHC subtype, being mPFS2 6 months (95%CI, 5-7) in TP, 7 months (95%CI, 5-9) in 
ER or PgR positive, and 8 months (95%CI, 6-10) in HRs negative tumors (p=0.44). Overall, treatment with second-line 
T-DM1 improved PFS, being mPFS2 7 months (95%CI, 5-9) in 371 patients treated with second-line T-DM1 and 6 
months (95%CI, 5-7) in 160 patients who received as second-line other HER-2 based treatments (p=0.003) (Table 1 
and Table 4). However, T-DM1 advantage in mPFS disappeared when we analyzed the subset of TP patients, which 
showed a mPFS2 of 6 months (95%CI, 5-7), both with second-line T-DM1 and other second-line treatments (p=0.17). 
In ER or PgR positive BC patients, mPFS2 was 7 months (95%CI, 4-10) if treated with second-line T-DM1, while it was 
5 months (95%CI, 3-7) if treated with another regimen (p=0.05). In HRs negative patients, second-line T-DM1, 
compared to other treatments, improved mPFS2, being 10 months (95%CI, 8-12), compared with 7 months of other 
treatments (95%CI, 6-8), respectively (p=0.04) (Table 4). We also addressed the effect of the regimen sequence 
between first-line and second-line treatments on PFS2 (see Figure 3 for more details), particularly with respect to 
having received or not a pertuzumab-based regimen in first-line, and having received or not T-DM1 in second-line. 
We focused especially on the patients who received T-DM1 in second-line, who represent also the major part of 
subjects who received a second-line treatment (371 patients, 69.9% of patients who received a second-line of 
treatment). Among them, 177 patients who received pertuzumab-based first-line had a mPFS2 with T-DM1 of 5.6 
months (95%CI, 4.5-6.6), while the 194 patients who did not receive pertuzumab, but were treated with a 
trastuzumab-based first-line, had a mPFS2 with T-DM1 of 8 months (95%CI, 6.6-9.6). This difference was statistically 
significant in the overall population (p = 0.02). The longer mPFS2 in patients who received T-DM1 after a 
trastuzumab-based first-line compared to those who received it after a pertuzumab-based first-line regimen was 
maintained in all the three IHC subgroups (TP, ER o PgR +, HRs -), without  significant differences among these three 
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groups (p=0.44). Concerning the160 patients who did notr receive T-DM1 in second-line, 109 had received 
pertuzumab in first-line and showed a mPFS2 of 6 months (95%CI, 4.2-6.8), while the 26 women who were not 
pretreated with pertuzumab in the first-line had a mPFS2 of 6 months (95%CI, 4.2-7.8), with no difference between 
the two groups overalland by ICH subtype. However, our study may be underpowered  for an adequate comparison 
between these latter patients’ subsets. Among the 31 patient having received T-DM1 as first-line, 25 received a 
second-line. Unfortunately, data on mPFS2 are unavailable.  
 
Overall survival 
Overall, in the 738 patients who contributed data to our analysis, mOS was 74 months (95%CI, 62-87). No differences 
in mOS emerged when we analyzed our population by IHC subtype, being 73 months (95%CI, 62-87) in TP patients, 
78 months (95%CI, 57-98) in ER or PgR positive patients and 76 months (95%CI, 56-95) in HRs negative patients 
(p=0.61). Furthermore, we analyzed data regarding the rates of OS at 2 and 3 years according to the IHC subtype and 
treatment received for metastatic disease in first and/or second line (Table 5). In the overall population, the 
administration of pertuzumab-based regimens as first-line followed by T-DM1 in second-line was associated with 
significantly lower rates of 2 and 3 year survival with respect to the other possible sequences, as it is clearly shown 
by the relative survival curves in Figure 2A (p=0.001). The statistical analysis by IHC subtypes showed that this lower 
OS rate at both 2 and 3 years was statistically significant in the TP and HRs negative subsets (p=0.02 and p=0.006, 
respectively), while no significant differences in OS emerged when we considered the ER or PgR positive patient 
subgroup (p=0.57). We represented these findings also by calculating the associated comparison of survival curves 
for TP, ER or PgR positive and HRs negative subgroups, respectively, reported  in Figures 2B, 2C and 2D. In the 
multivariate analysis (supplementary Table 2) the only three variables related to a worse OS were: not having 
received a pertuzumab-based regimen as a first-line treatment (HR 2.0; 95% CI 1.4 - 2.9; p < 0.0001), not having 
received T-DM1 in second-line (HR 1.5; 95% CI 1.1 - 2.0; p = 0.008) and  a baseline Ki 67 >20% (HR 1.59; 95% CI 1.1 – 
2.4; p = 0.021). Moreover, multivariate analysis showed no significant effect of the ICH subgroup categories on OS. 
Thus, the distinctive effect of the HRs expression patterns on OS observed in the non-parametric test emerges only if  
treatment sequences are considered separately. This  confirms the hypothesis of HRs expression relevance when 
considering the treatment choice. 
 
DISCUSSION 
We conducted an observational study of 738 HER2-positive metastatic BC patients who were treated at 45 Italian 
Cancer Centers in the time frame between May 2003 and November 2017. All of them had received at least one 
cycle of pertuzumab-based treatment in first-line and/or at least one T-DM1 cycle in the second or following lines of 
therapy. Data analysis was performed to assess if the expression of HRs was related to significant differences in 
terms of key patient-and/or (other than HR) disease-related features and/or treatment outcomes.  
Within our study population, we observed some differences in disease features according to HRs expression. In more 
detail, TP patients had a significant higher prevalence of bone-only disease and a reduced occurrence of brain 
metastases (p=0.02 and 0.06, respectively). Moreover, in the TP and in patients with tumors with only one HR-
positive tumors, there was also a greater proportion of patients who had a late development of metastases, i.e.,  
after the first 3 years from the initial diagnosis, with respect to the HRs negative subgroup (p=<0.0001).  
When we analyzed the overall benefit from the treatment received for metastatic disease, mPFS1 seemed not to be 
affected by  HRs expression (p=0.53). However, as shown in Table 3, in patients treated with pertuzumab-
trastuzumab-taxane regimen, mPFS1 was significantly higher, being 16 months (95%CI, 13-19), compared with 9 
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months of other treatments (p<0.0001). Interestingly, this improvement in terms of mPFS1 was recorded across all 
the three IHC subtypes analyzed, suggesting a benefit of pertuzumab-based treatment independently on HRs 
expression (Table 3, Figure 1). This was confirmed by the multivariate analysis which also showed that HRs 
expression pattern did not have a confounding effect on this outcome.  
Among the 531 patients evaluable for the second-line treatment outcomes, overall, mPFS2 to T-DM1 treatment was 
7 months, in comparison with 6 months for the other second-line treatments (p = 0.003). The improvement related 
to second-line T-DM1 didn’t emerge when considering only TP patients, which had a mPFS2 of 6 months for both T-
DM1 and for other treatments (p=0.17, Table 4). Conversely, in HRs negative tumors, the benefit of second-line T-
DM1 was clearly evident, with 10 months of mPFS2 versus 7 months of other treatments (p 0.04). These findings 
were based on a calculation performed on all patients who received a second-line, without making any distinction 
between those who had received a pertuzumab-based regimen in the first-line and those who hadn’t. The intriguing 
result that shows a relatively higher mPFS2 advantage in HER2+ HRs negative BC patients supports the hypothesis 
according to which HRs negative tumors might have  a higher sensitivity to chemotherapy and HER2-blocking agents 
[12]. Whereas, the absence of a mPFS2 advantage associated with T-DM1 compared to other treatments in TP 
patients, besides the possible lower sensitivity of this subgroup to HER2-blockers, may be also at least partly 
attributed to the fact that patients with HRs positive tumors received endocrine maintenance therapy after 
trastuzumab or trastuzumab/pertuzumab-based therapy. This was not an option for patients who received T-DM1. 
The additive effect of these two factors may represent a plausible explanation for the lack of an evident advantage 
by T-DM1 in TP BC patients with respect to other therapeutic options. Moreover, results showed that among the371 
patients who received T-DM1 as second-line, those receiving it after first-line pertuzumab  (N:177)had a mPFS2 of 
5.6 months, which was significantly lower than the 8 months of mPFS2 for  those patients who received T-DM1 in 
second-line after a first-line regimen not containing pertuzumab (N:194) (p 0.02). This evidence supports  a lower 
efficacy of this agent when delivered immediately after pertuzumab, independently on the ICH subtype. This finding 
suggests a possible cross-resistance mechanism between the pertuzumab-trastuzumab double-block and T-DM1, 
which is stronger than a possible similar cross-resistance mechanism existing between trastuzumab and T-DM1. 
No differences in OS emerged when we analyzed our entire population by IHC subtype. We also analyzed the clinical 
outcomes of our study population on the basis of the treatment-sequences received for metastatic disease. Overall, 
the administration of pertuzumab-based regimens as first-line and subsequently T-DM1 as second-line was 
significantly associated with a lower rate of 2- and 3-year survival (p=0.001, Table 5). This result is congruent with 
what we observed when analyzing mPFS2. However, differently than mPFS2 (where this lower benefit was present in 
all the IHC subtypes), when analyzing OS, the worse outcome of the sequence pertuzumab  T-DM1 in first and 
second-line did not emerge for all the three IHC subgroups. In fact, these unfavorable OS rates for sequential 
pertuzumabT-DM1 treatments were statistically significant both in TP and in HRs negative subsets (p=0.02 and 
p=0.006, respectively), but not in patients with ER or PgR positive tumors (p=0.57). This finding could be due to some 
underlying biological mechanism that needs interpretation, although selection bias and confounding factors cannot 
be excluded, since the effect of the IHC subtype on OS was not confirmed in  multivariate analysis. 
Among HER2-positive tumors, the expression pattern of HRs apparently defines distinct subtypes. Specifically, the TP 
subtype could be considered as the subset which most closely resembles the luminal-like tumors, in comparison to 
HER2 overexpressing tumors that express only one or none of the HRs [9,10]. This hypothesis is supported in our 
case series by the fact that TP patients had a significant higher prevalence of bone-only disease, a lower prevalence 
of brain metastases, and showed a greater proportion of “late” metastases, reinforcing the data already published in 
this regard [13]. Moreover, TP patients showed distinctive characteristics also regarding treatment outcomes, since 
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the subgroup showed no PFS benefit and lower OS rates, together with HRs negative subset, when receiving T-DM1 
in second-line. Therefore, the contemporary expression of HER2 and both HRs may represent a relevant element to 
be considered  when choosing the treatment strategy. 
To our knowledge, this is the first study to evaluate the efficacy of new anti-HER2 therapeutic strategies in relation 
to HRs expression in metastatic BC patients, while making a clear distinction between patients with HER2-positive BC 
that express both HRs, only one of them, or no HRs at all. A differential sensitivity to combined HER2-blocking agents 
and chemotherapy according to HR status was consistently reported both in the early and in the advanced setting, 
giving some clues on the possible role of maintenance endocrine therapy [14-20]. A retrospective study performed in 
HER2-positive metastatic BC patients suggested that an expression of ER in ≥ 30% of tumor cells was predictive of 
reduced response to chemotherapy plus trastuzumab, but at the same time it indicated patients that could get a 
benefit from a maintenance endocrine treatment added to trastuzumab administration after the induction with 
chemotherapy and trastuzumab [20]. Further data confirm the important role of maintenance endocrine treatment 
in HER2+ mBC patients also when treated with the pertuzumab-trastuzumab double block. 
Since 2012, a paradigm shift was observed in the management of HER2-positive metastatic BC following the results 
from the CLEOPATRA [21], the EMILIA [7], and the TH3RESA trials [11]. The first study demonstrated a significant 
increase in both PFS and OS when adding pertuzumab to trastuzumab plus docetaxel. This benefit was less evident in 
HR-positive BC patients. However, these patients did not receive maintenance hormonal therapy. Recently, our 
group carried out a retrospective observational study in 264 HER2-positive metastatic BC patients treated with a 
pertuzumab-based regimen as a first-line. Results were consistent with the findings from the CLEOPATRA trial. 
Differently from the pivotal trial, in our patient population maintenance endocrine therapy was added to 
pertuzumab-trastuzumab maintenance in 103 patients, who had the most favorable clinical outcomes in terms of 
PFS and OS, suggesting that the double-maintenance therapy (HER2 blockade and endocrine treatment) could have a 
relevant positive clinical impact in patients with HER2-positive/HR-positive BC [22]. In the present analysis,  patients 
treated with pertuzumab/trastuzumab-based regimens experienced a mPFS1 that was comparable to that of the 
pivotal trial, being 16 months, vs 9 months in those patients who received  other first-line treatments (p<0.0001). A 
clear advantage from pertuzumab/trastuzumab-based regimens was evident in all analyzed IHC subtypes, including 
TP and one HR positive subgroups,  who, in this study cohort, received also endocrine maintenance treatment, 
which may theoretically “regain” the “PFS loss” in the HRs-positive patients, presumably less responsive to HER2-
blocking agents. Besides the proven impact of endocrine treatment received in the metastatic setting, we performed 
a further analysis to evaluate whether endocrine treatment received in the neoadjuvant or adjuvant setting miay 
have had an impact on mPFS1 and mPFS2. As we show in Supplementary Table 3, among the 491 patients who were 
initially diagnosed with an early or locally advanced disease, 298 received endocrine treatment as neodjuvant or 
adjuvant therapy, while 193 did not. Overall, the patients who had received an endocrine therapy in the early setting 
had a mPFS1 of 12 months versus 11 months of patients who did not. This difference was not significant (p=0.14). 
Neither significant differences were found when comparing the mPFS2 of these same two groups (p=0.54). When 
this same comparison was performed in patients stratified by  IHC subgroups, in TP patients, who had received 
endocrine therapy in the early setting, we verified some impact on the mPFS1 outcome. In fact, mPFS1 for TP 
patients who had received neoadjuvant/adjuvant endocrine therapy was 11 months compared to 16 months of 
patients who did not . This difference was at the limit of stastistical significance (p=0.05). We may thus hypothesize 
that the worse outcome in terms of PFS1 for TP patients having received endocrine therapy in the early setting 
maybe related to the fact that maintenance endocrine treatment for this patients yielded less PFS1 advantage due to 
the onset of resistance to anti-hormonal agents. At the same time, this result confirms, at least indirectly, the 
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positive impact of endocrine maintenance therapy in TP patients for PFS1. In this same analysis, no relevant impact 
on mPFS2 was found for endocrine treatment in the early setting of TP patients (p=0.26). Moreover, the TP positive 
subgroup, as defined based on IHC,  was the only one to show some impact of endocrine treatment in early setting 
on outcomes verified in the metastatic setting. In fact, for both the remaining subgroups, ER or PR positive patients 
and HRs negative patients, administration of endocrine treatment in the early setting did not  impact either mPFS1 
(respective p-values were 0.48 and 0.86) or mPFS2 (respective p-values were 0.92 and 0.24). It is noteworthy that 
the 41 patients in the HRs IHC subgroup, who had received endocrine treatment in the early setting, had initially a 
HRs positive disease. Overall, this further analysis confirms the distinct nature of TP disease and the particular 
importance of anti-hormonal treatment in this subgroup. 
The EMILIA trial compared T-DM1 to lapatinib and capecitabine for treatment of advanced HER2-positive BC in 
second-line or beyond [7]. The experimental arm had superior PFS and OS. Subgroup analysis failed to show a 
differential impact of the treatment based on HRs status. Our group carried out a retrospective, observational 
analysis of T-DM1 clinical activity in 250 HER2-positive metastatic BC patients [23]. Overall, our results were 
comparable with those from randomized trials and, similarly to what was found in those studies, no differences in 
clinical outcomes emerged when we analyzed our population by HRs status (p=0.29). However, when analyzed in 
relation to pertuzumab-pretreatment, patients who received second-line T-DM1 had mPFS2 and mOS of 3 and 12 
months respectively (p=0.0001) when pertuzumab-pretreated, and 8 and 26 months when pertuzumab-naïve 
(p=0.06). Conversely, in third-line and beyond, mPFS and mOS to T-DM1 were 16 and 18 months in pertuzumab-
pretreated (p=0.05), and 6 and 17 months in pertuzumab-naïve patients (p=0.30). The results of this study regarding 
the PFS of the second-line of treatment and OS are consistent with those from the present study analyzing a larger 
population, when pertuzumab pre-treatment is considered. In fact, in the current analysis, patients pre-treated with 
pertuzumab who received T-DM1 in second-line had a PFS advantage with respect to those not receiving second-line 
T-DM1 (p=0.03). Moreover, in the cohort of the present study, receiving T-DM1 in second-line, immediately after 
pertuzumab, resulted detrimental in terms of OS with respect to receiving it after a trastuzumab-based first-line. As 
we mentioned before, this might be related to a possible transient cross-resistance between the two agents, 
although the outcome could be explained also by a selection bias, considering that patients who received T-DM1 as 
third or more advanced lines presumably had a more indolent disease which allowed several lines of treatments, 
compared to patients treated with T-DM1 as second-line. In the current study, a further analysis to explore the OS 
rates in the different IHC subgroups showed that the aforementioned difference in OS rates according to sequential 
pertuzumab and T-DM1 treatment was statistically significant in the TP and HRs negative subsets (p=0.006). 
Conversely, it was not recorded in patients with ER or PgR-positive tumors (p=0.57). Specifically, TP BC could have 
more potential to develop chemotherapy resistance related to the activation of the ER pathway [24]. This 
mechanism could be less evident in HER2-positive tumors that express low levels of HRs or only one of them. At the 
same time, our results in HRs negative tumors might be related to an intrinsic aggressiveness of the disease in this 
subset [25]. 
Overall, our results are consistent with some previously emerged evidences on the reduced activity of T-DM1 when 
given immediately after pertuzumab-based regimens. A retrospective study investigating the efficacy of T-DM1 after 
pertuzumab-based combination therapy showed shorter median duration of T-DM1 therapy (4.0 months) in patients 
who had received prior pertuzumab-based regimens. When discussing this latter evidence, the authors ascribed it at 
least partially to the retrospective nature of the research and the relatively high percentage of de novo stage IV 
patients (44%)[26]. However, the present study included only 33.5% of de novo stage IV patients. Therefore, it is 
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plausible that the lower efficacy of T-DM1 in patients pretreated with pertuzumab/trastuzumab-based combinations 
might be the result other mechanisms. 
Evidence of lower efficacy of T-DM1 when administered immediately after a pertuzumab-based regimen was also 
found in prospective studies. The preliminary results of the PERNETTA study conducted in 210 patients with HER2-
positive metastatic BC treated with a pertuzumab-containing regimen in first-line and with T-DM1 as second-line, 
showed that mPFS in second-line treatment was lower (5.3 months) than that recorded in the pivotal trial, where 
patients treated with second-line T-DM1 were pertuzumab-naïve [27]. Furtherly, a recently published prospective 
study carried out in 42 Japanese HER2-positive metastatic BC patients has shown that the mPFS following T-DM1 
administration was lower in the group pretreated with pertuzumab/trastuzumab-based regimens compared to the 
group of patients who received trastuzumab-based regimens (2.8 months vs 7.8 months, respectively, p = 0.0030) 
[28]. 
The present study has some limitations. It has a retrospective design, which per se represents a source of 
confounding and bias. Selection bias may be fueled by the intrinsic characteristics of our patients’ disease, which 
may have affected at some extent treatment outcomes. In more detail, patients who received T-DM1 as third or 
more advanced lines might have a more indolent disease which allowed them to receive T-DM1 after other 
treatment-lines. In addition, since we address treatment outcomes by cancer subtype, the lack of centralized 
evaluation by either IHC or NGS techniques may lessen our confidence in the results observed, although quality 
controls are in place at the participating centres. In addition, for patients who provided data to this analysis, the 
follow-up period was relatively short. Our study also has several strengths. This is the first report to address 
outcomes of treatment sequences in a quite large cohort of HER2-positivemetastatic BC patients in light of the 
biological characteristics of the disease, with a specific focus on HRs expression. In addition, our study was 
conducted in patients treated outside clinical trials. As such, it faithfully reproduces the current clinical practice. 
Numerous are the evidences related to the biological differences and response to treatment within the subgroup 
globally defined as HER2-positive BC. This is the first report that has consistently shown a  response to novel anti-
HER2 treatments differing by HRs status. Since HER2-positive BC evolves under the selective pressure of targeted 
agents, it is of paramount importance recognizing resistance pathways related to the exposure to novel treatments 
according to a given sequence. Our results provides a strong rationale to perform studies aiming at a deeper 
understanding of the intrinsic biology of HER2-positive disease, in order to optimally combine the available hormonal 
and anti-HER2 therapy treatments to overcome both endocrine and anti-HER2 resistance. The final goal is the 
achievement of decisions driving to the most effective therapeutic choice at an individual-patient level.  
In conclusion, breast cancer biology is of uttermost relevance for optimizing treatment and better interpreting the 
clinical outcomes. The central role of the HRs and the HER2 pathways in sustaining BC development and growth has 
been clearly established. The expression of both HRs concomitantly with the overexpression of HER2 depicts a TP 
subtype, that may have distinct clinical manifestation and treatment outcomes compared to the other HER2-positive 
subtypes. Results from this historical cohort support our hypothesis. In more details, in patients with TP tumors, we 
actually observed  clinical manifestations that more closely resemble those of luminal A patients, with higher rates of 
bone-only disease and lower rate of brain metastasis. No differences emerged in terms of first-line treatment 
outcomes in TP patients with respect to the other subsets, being the benefit of pertuzumab-based treatment 
consistent in all subgroups. However, the PFS gain due to the administration of T-DM1 as second-line that was 
observed in the overall population seems to disappear when analyzing the TP subgroup, giving a hint on a possible 
additional mechanism of resistance towards HER2-blockers in this subset of patients. On this basis, our data confirm 
the need for further exploration of TP BC throughout the conduct of ad-hoc designed, appropriately sized, 
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prospective trials. These latter studies will be aimed to clarify the extent to which treatment outcomes in HER2-
positive metastatic BC treated with sequences including hormonal therapy  and novel anti-HER2 agents may differ 
depending on the co-expression of both the HRs vs only one of the two. This research will provide data on 
“canonical” treatment outcomes, which may be more appropriately interpreted in light of the results from the 
annexed tasks and experimental designs focused on the underlying mechanisms regulating the development of 
resistance across the different subtypes of HER2-postive metastatic BC patients. A possible equalizer for outcome 
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Table 1. Main baseline characteristics of the study population (Number: 738) 
Characteristics Patients, Number (%) 




































Immunoistochemical subtype at diagnosis of 
metastatic disease 
Triple Positive 













































Number of metastatic sites  







Abbreviations: ER, estrogen receptor; PgR, progesteron receptor 
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Table 2. Sites of metastases sites according to molecular subtype  
Molecular subtype Bone only Visceral Brain 
Triple Positive 28 (8.8%) 221 (69.5%) 66 (20.8%) 
ER or PgR positive 13 (9.2%) 97 (68.2%) 42 (29.6%) 
HRs negative 10 (3.6%) 189 (68.2%) 77 (27.8%) 
p 0.02 0.94 0.06 
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor 
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Table 3. Progression Free Survival at first line treatment (PFS1) overall and according to molecular subtype 
and type of treatment received  
Molecular subtype Pertuzumab as first line median PFS (months, CI) p  
Overall Yes 16 (13-19) <0.0001 No 9 (8-10) 
Triple Positive Yes 15 (12-18) <0.0001 No 8 (6-10) 
ER or PgR Positive Yes 15 (10-20) 0.0004 No 9 (7-11) 
HRs negative Yes 20 (16-24) <0.0001 No 9 (8-10) 
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor 
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Table 4. Progression Free Survival at second line treatment (PFS2) overall and according to molecular 
subtype and type of treatment received   
Molecular subtype T-DM1 as second line median PFS (months, CI) p 
Overall Yes 7 (5-9) 0.003 No 6 (5-7) 
Triple Positive Yes 6 (5-7) 0.17 No 6 (5-7) 
ER or PgR Positive Yes 7 (4-10) 0.05 No 5 (3-7) 
HRs negative Yes 10 (8-12) 0.04 No 7 (6-8) 
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor 
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Table 5. Overall Survival at 2 and 3 years according type of treatment received in first and second-line and 
molecular subtype (Tarone Ware test) 




2 yr OS  
(%) 
3 yr OS  
(%) p 
Overall  No No 88.8 84.7 
0.001 Yes No 89.1 78.5 No Yes 92.1 82.9 
Yes Yes 78 62.7 
Triple Positive No No 87.1 83.6 
0.02 
 
Yes No 89.1 71.1 
No Yes 93.4 86.3 
Yes Yes 80.2 66.0 
ER or PgR Positive No No 88.9 88.9 
0.57 Yes No 87.3 87.3 No Yes 91.8 83.0 
Yes Yes 83.9 73.1 
HRs negative No No 89.9 84.5 
0.006 
 
Yes No 89.9 84.3 
No Yes 90.7 77.9 
Yes Yes 72.3 52.5 
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Figure 1. The comparison of progression-free survival in the firs-line of treatment (PFS1) between 
patients that received a pertuzumab-based regimen (Pert) and those who didn’t (No Pert) in the 
overall population (A), in triple positive patients (B), in Er o PgR positive patients (C) and in HRs 
negative patients (D). Er: Estrogen receptor; PgR: Progesterone receptor; HRs: Hormone Receptors.
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Figure 2. The comparison of overall survival (OS) between patients that didn’t receive a pertuzumab-
based regimen in first-line and didn’t receive T-DM1 as a second-line of treatment (No/No, red 
colour), patients that didn’t receive a pertuzumab-based regimen in first-line and received T-DM1 as 
a second-line of treatment (No/Yes, green colour), patients that received a pertuzumab-based 
regimen in first-line and T-DM1 as a second-line of treatment (Yes/Yes, grey colour)  and those who 
received a pertuzumab-based regimen in first-line and didn’t receive T-DM1 as a second-line of 
treatment (Yes/No, blue colour). The comparison was done in the overall population (A), in triple 
positive patients (B), in Er o PgR positive patients (C) and in HRs negative patients (D). The adjacent 
percentages to each survival curve refer to the 3-year survival rate.
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Figure 3:  first line and second line of patients divided according to if they received Pertuzumab or 
not in first line and T-DM1 or not in second line. Correlation between sequences of treatment and 3 
years OS rate of patients, divided according to immunohistochemistry subtype. 
ER: estreogen receptor; HRS: hormone receptors; OS: Overall survival;  P: Pertuzumab; PFS: 
progression free survival PR: progesteron receptor; P based regimen: Pertuzumab-based regimen; P 
Yes I: received Pertuzumab in first-line; T-DM1 Yes II: received T-DM1 in secondline; P No I: didn’t a 
Pertuzumab-based regimen in first-line; T-DM1 No II: didn’t receive T-DM1 in second-line 
 
 
About half of breast cancers positive for human epidermal growth factor (HER2) also express hormone receptors but 
the impact of hormone receptor status on the success of HER2-directed treatments is not fully explored. Here the 
authors retrospectively assessed tumour behavior and treatment outcomes in 738 women with HER2+ metastatic 
breast cancer treated with new generation anti-HER2 agents. Distinct hormone receptor expression patterns 
significantly affected the progression free and overall survival, justifying further studies to define optimal treatment 
regimens and the interplay between hormone receptor and HER2 signaling.  
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